Ceftolozane/tazobactam: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: Antibiotic (cephalosporin/beta-lactamase inhibitor combination) | ||
*Dosage Forms: | *Dosage Forms: IV | ||
*Common Trade Names: | *Common Trade Names: Zerbaxa | ||
==Adult Dosing== | ==Adult Dosing== | ||
*1.5 grams (1gm ceftolozane/0.5gm tazobactam) IV q8H | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
N/A | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult - 750mg IV q8hr for moderate renal impairment, 375mg IV q8hr for severe impairment | ||
**Pediatric | **Pediatric - N/A | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult - N/A | ||
**Pediatric | **Pediatric - N/A | ||
==Contraindications== | ==Contraindications== | ||
| Line 28: | Line 30: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: | ||
*Metabolism: | *Metabolism: N/A | ||
*Excretion: | *Excretion: Renal (100%) | ||
*Mechanism of Action: | *Mechanism of Action: | ||
[[Category:ID]] | [[Category:ID]] | ||
Revision as of 06:01, 28 June 2017
General
- Type: Antibiotic (cephalosporin/beta-lactamase inhibitor combination)
- Dosage Forms: IV
- Common Trade Names: Zerbaxa
Adult Dosing
- 1.5 grams (1gm ceftolozane/0.5gm tazobactam) IV q8H
Pediatric Dosing
N/A
Special Populations
- Pregnancy Rating: B
- Lactation:
- Renal Dosing
- Adult - 750mg IV q8hr for moderate renal impairment, 375mg IV q8hr for severe impairment
- Pediatric - N/A
- Hepatic Dosing
- Adult - N/A
- Pediatric - N/A
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism: N/A
- Excretion: Renal (100%)
- Mechanism of Action: